Literature DB >> 8780396

Role of plasminogen activator inhibitor in the reciprocal regulation of bovine aortic endothelial and smooth muscle cell migration by TGF-beta 1.

E Petzelbauer1, J P Springhorn, A M Tucker, J A Madri.   

Abstract

Vascular endothelial and smooth muscle cells exhibit reciprocal migratory responses after transforming growth factor (TGF)-beta 1 treatment. Endothelial cells exhibit a decreased migratory rate and smooth muscle cells exhibit an increased migratory rate. Previous studies have demonstrated increases in extracellular matrix and integrin synthesis and expression in response to TGF-beta 1. In this report, we illustrate the roles of plasminogen activator inhibitor in modulating the migratory rates in these two cell types. Endothelial cells appear to require a proteolytic phenotype for rapid migration, whereas vascular smooth muscle cells appear to require an anti-proteolytic phenotype. Modulation of proteinase/anti-proteinase activity ratios was accomplished via TGF-beta 1 induction, addition of exogenous plasminogen activator inhibitor, addition of anti-catalytic antibodies directed against urokinase plasminogen activator, overexpression of plasminogen activator inhibitor utilizing stable transfectants, and the use of vitronectin as a substratum. The reciprocal migratory behaviors exhibited by these two vascular cell types in response to TGF-beta 1 is discussed in the context that these two vascular cell types utilize distinct adhesive and signaling pathways in their interactions with extracellular matrix components and responsiveness to proteolytic activity.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8780396      PMCID: PMC1865168     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  49 in total

1.  Synthesis of a fibrinolytic activator and inhibitor by endothelial cells.

Authors:  D J Loskutoff; T E Edgington
Journal:  Proc Natl Acad Sci U S A       Date:  1977-09       Impact factor: 11.205

2.  Limited cleavage of cellular fibronectin by plasminogen activator purified from transformed cells.

Authors:  J P Quigley; L I Gold; R Schwimmer; L M Sullivan
Journal:  Proc Natl Acad Sci U S A       Date:  1987-05       Impact factor: 11.205

3.  Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production.

Authors:  A D Miller; C Buttimore
Journal:  Mol Cell Biol       Date:  1986-08       Impact factor: 4.272

4.  Basement membrane collagen: degradation by migrating endothelial cells.

Authors:  T Kalebic; S Garbisa; B Glaser; L A Liotta
Journal:  Science       Date:  1983-07-15       Impact factor: 47.728

5.  Measurement of protein using bicinchoninic acid.

Authors:  P K Smith; R I Krohn; G T Hermanson; A K Mallia; F H Gartner; M D Provenzano; E K Fujimoto; N M Goeke; B J Olson; D C Klenk
Journal:  Anal Biochem       Date:  1985-10       Impact factor: 3.365

6.  Plasminogen and tissue-type plasminogen activator bind to immobilized fibronectin.

Authors:  E M Salonen; O Saksela; T Vartio; A Vaheri; L S Nielsen; J Zeuthen
Journal:  J Biol Chem       Date:  1985-10-05       Impact factor: 5.157

7.  Association of chronic stress with plasminogen activator inhibitor-1 in healthy middle-aged men.

Authors:  K Räikkönen; R Lassila; L Keltikangas-Järvinen; A Hautanen
Journal:  Arterioscler Thromb Vasc Biol       Date:  1996-03       Impact factor: 8.311

8.  The opposing effects of basic fibroblast growth factor and transforming growth factor beta on the regulation of plasminogen activator activity in capillary endothelial cells.

Authors:  O Saksela; D Moscatelli; D B Rifkin
Journal:  J Cell Biol       Date:  1987-08       Impact factor: 10.539

9.  Urokinase-type plasminogen activator is induced in migrating capillary endothelial cells.

Authors:  M S Pepper; J D Vassalli; R Montesano; L Orci
Journal:  J Cell Biol       Date:  1987-12       Impact factor: 10.539

10.  Association of a plasminogen activator inhibitor (PAI-1) with the growth substratum and membrane of human endothelial cells.

Authors:  E G Levin; L Santell
Journal:  J Cell Biol       Date:  1987-12       Impact factor: 10.539

View more
  7 in total

1.  Placenta growth factor (PlGF), a novel inducer of plasminogen activator inhibitor-1 (PAI-1) in sickle cell disease (SCD).

Authors:  Nitin Patel; Nambirajan Sundaram; Mingyan Yang; Catherine Madigan; Vijay K Kalra; Punam Malik
Journal:  J Biol Chem       Date:  2010-03-29       Impact factor: 5.157

2.  Evidence for a role of collagen synthesis in arterial smooth muscle cell migration.

Authors:  E F Rocnik; B M Chan; J G Pickering
Journal:  J Clin Invest       Date:  1998-05-01       Impact factor: 14.808

3.  Endothelial cell integrin laminin receptor expression in multiple sclerosis lesions.

Authors:  R A Sobel; J R Hinojoza; A Maeda; M Chen
Journal:  Am J Pathol       Date:  1998-08       Impact factor: 4.307

4.  Modulation of glioma cell invasion and motility by adenoviral gene transfer of PAI-1.

Authors:  G O Hjortland; K Bjørnland; S Pettersen; S S Garman-Vik; E Emilsen; J M Nesland; O Fodstad; O Engebraaten
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

Review 5.  Integration of non-SMAD and SMAD signaling in TGF-beta1-induced plasminogen activator inhibitor type-1 gene expression in vascular smooth muscle cells.

Authors:  Rohan Samarakoon; Paul J Higgins
Journal:  Thromb Haemost       Date:  2008-12       Impact factor: 5.249

6.  In vitro wounding: effects of hypoxia and transforming growth factor beta1 on proliferation, migration and myofibroblastic differentiation in an endothelial cell-fibroblast co-culture model.

Authors:  Martin Oberringer; Claudia Meins; Monika Bubel; Tim Pohlemann
Journal:  J Mol Histol       Date:  2007-09-04       Impact factor: 2.611

7.  TGF-beta1-induced plasminogen activator inhibitor-1 expression in vascular smooth muscle cells requires pp60(c-src)/EGFR(Y845) and Rho/ROCK signaling.

Authors:  Rohan Samarakoon; Stephen P Higgins; Craig E Higgins; Paul J Higgins
Journal:  J Mol Cell Cardiol       Date:  2008-01-03       Impact factor: 5.000

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.